Congenital Hyperinsulinism

Area of Science:

• Pediatric Endocrinology
• Medical Genetics

Background:

• Hyperinsulinemic hypoglycemia (HH) is common in neonates, especially those born to diabetic mothers or with abnormal birth weights.
• Immediate management involves frequent feedings or IV glucose; glucagon is an option if IV access is difficult.
• Persistent HH warrants evaluation for congenital hyperinsulinism (CHI), a group of genetic disorders causing excessive insulin secretion.

Purpose of the Study:

• To review the pathogenesis, genetic basis, and clinical aspects of congenital hyperinsulinism.
• To outline diagnostic approaches and management strategies for CHI.
• To discuss the prognosis and risk of hypoglycemic brain injury in affected infants.

Main Methods:

• Literature review focusing on genetic defects in pancreatic beta-cell insulin secretion.
• Analysis of clinical presentations, diagnostic criteria, and treatment modalities for CHI.
• Examination of the impact of recurrent hypoglycemia on neurodevelopment.

Main Results:

• CHI results from genetic defects affecting insulin secretion pathways in pancreatic beta-cells.
• Management includes pharmacologic therapies and surgical or curative interventions.
• Infants with CHI face significant risks of hypoglycemic brain injury due to high glucose demands of the developing brain.

Conclusions:

• CHI is a serious genetic disorder requiring prompt diagnosis and multidisciplinary management.
• Understanding the genetic underpinnings is key to targeted therapies and improved outcomes.
• Preventing severe hypoglycemia is paramount to mitigate long-term neurological sequelae.